Found: 5
Select item for more details and to access through your institution.
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.
- Published in:
- Translational Psychiatry, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41398-023-02435-0
- By:
- Publication type:
- Article
Efficacy, Safety, and Tolerability of Ansofaxine (LY03005) Extended-Release Tablet for Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2 Clinical Trial.
- Published in:
- International Journal of Neuropsychopharmacology, 2022, v. 25, n. 3, p. 252, doi. 10.1093/ijnp/pyab074
- By:
- Publication type:
- Article
Association of ABCB1 Gene Polymorphisms with Efficacy and Adverse Reaction to Risperidone or Paliperidone in Han Chinese Schizophrenic Patients.
- Published in:
- 2016
- By:
- Publication type:
- Letter
Genome-Wide Association Study Suggested the PTPRD Polymorphisms Were Associated With Weight Gain Effects of Atypical Antipsychotic Medications.
- Published in:
- Schizophrenia Bulletin, 2016, v. 42, n. 3, p. 814, doi. 10.1093/schbul/sbv179
- By:
- Publication type:
- Article
High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.
- Published in:
- Neuropsychiatric Disease & Treatment, 2015, v. 11, p. 1161, doi. 10.2147/NDT.S72367
- By:
- Publication type:
- Article